Initial chemotherapeutic treatment triggers a stressrelated response, which can lead to an increase in the expression of survival proteins. In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state. We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E. The hyperphosphorylation of 4E-BP1 correlated with G2/M accumulation and with an increase in the phosphorylation of cdk1 substrates. Cotreatment with a histone deacetylase inhibitor (an indirect inhibitor of cdk activity), purvalanol A and roscovitine (direct cdk inhibitors), and the reduction of cyclin B expression using RNA interference decreased the hyperphosphorylation of 4E-BP1 in PTX treated cells. The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells. Taken together, our data suggest that PTXincreases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.
Introduction
Chemotherapeutic treatment leads to the activation of conflicting signaling pathways that both promote and inhibit cell death (Johnstone et al., 2002) . Paclitaxel (PTX) is a drug currently used in the treatment of ovarian and metastatic breast cancer (Vogel and Nabholtz, 1999; du-Bois, 2001 ). PTX stabilizes microtubules, which interferes with the formation of the mitotic spindle, inducing a mitotic block (Jordan et al., 1993) . The cytotoxic effects of PTX have been linked to its inhibition of microtubule function (Mollinedo and Gajate, 2003) and the upregulation of the proapoptotic proteins, Bax (Srivastava et al., 1998) and Bak (Wang et al., 2000) and the downregulation and inactivation of the antiapoptotic protein, Bcl-2 (Wang et al., 2000; Ferlini et al., 2003) .
Concomitantly, PTX enhances the expression of survival factors. PTX increases the expression of the inhibitor of apoptosis (IAP), survivin (O'Connor et al., 2002) and the cyclin-dependent kinase inhibitor protein, p21/WAF1/Cip1 (Mitsuuchi et al., 2000; Heliez et al., 2003) . PTX also activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway which positively impacts growth and is an important regulator of cap-dependent translation (Vivanco and Sawyers, 2002) . Reportedly, PTX induces the phosphorylation of the proapoptotic protein, Bad, through the PI3K/Akt pathway, which negatively regulates its proapoptotic function (Mabuchi et al., 2002) .
Aberrant translation initiation is emerging as an important tenet of cancer progression and investigations into the cellular mechanisms that alter the rate of capdependent translation initiation are the subject of increasing scrutiny. The eukaryotic initiation factor 4E (eIF-4E) has received widespread attention due to studies which indicate that eIF-4E is an oncogene (Lazaris-Karatzas et al., 1990) and that malignancy progression correlates with an increase in the cellular concentration of eIF-4E (De-Benedetti and Harris, 1999; Rosenwald et al., 1999; Zimmer et al., 2000) . Additionally, the increased cellular content of eIF-4E is thought to confer a survival advantage to cells that protects against apoptosis by mechanisms that are only beginning to be understood (Li et al., 2002; Graff and Zimmer, 2003) .
During cap-dependent translation, eIF-4E binds to the 7-methyl-GpppN-cap structure at the 5 0 end of the mRNA, which promotes the formation of the eIF-4F initiation complex and ribosome binding (Meric and Hunt, 2002) . The rate of cap-dependent translation of a specific mRNA is dependent upon the amount of active eIF-4E and the accessibility of its 5 0 cap (Graff and Zimmer, 2003) . Thus, mRNAs containing highly structured 5 0 UTRs, which include cyclin D1 and VEGF, will be translated at a higher rate as the amount of active eIF-4E increases.
The activity of eIF-4E is regulated through various mechanisms. eIF-4E is phosphorylated on Ser-209 (Joshi et al.,1995) , which increases its affinity for the cap structure, enhancing cap-dependent translation (Minich et al., 1994) , although this concept has been challenged by a recent study (Scheper et al., 2002) . eIF-4E activity is also a function of protein levels. As mentioned previously, the overexpression of eIF-4E correlates with malignancy progression, resistance to chemotherapy (Wendel et al., 2004) , and an increase in the expression of mitogenic factors. In addition to protein levels, the amount of active eIF-4E is regulated by its association with small inhibitory 4E binding proteins (4E-BPs), of which 4E-BP1/PHAS I is the most extensively studied.
Binding of 4E-BP1 to eIF-4E prevents the assembly of the eIF-4F complex by inhibiting binding of eIF-4E to eIF-4G (Mader et al., 1995) . The phosphorylation of 4E-BP1 reduces its binding affinity for eIF-4E and promotes its release from eIF-4E, thereby increasing eIF-4E functional activity Pause et al., 1994; Raught and Gingras, 1999) .
Growth and survival signals lead to the phosphorylation of 4E-BP1 on multiple residues. The serinethreonine kinase mTOR/FRAP, the downstream effector of the PI3K/Akt pathway, is responsible for the phosphorylation of Thr-37 and Thr-46. The phosphorylation of these residues is thought to prime 4E-BP1 for further phosphorylation events , which are thought to be required to secure its release from eIF-4E Mothe-Satney et al., 2000a, b) The kinases responsible for these phosphorylations have not been clearly defined. However, the ATM kinase (Yang and Kastan, 2000) and cyclin B-cdk1 (Heesom et al., 2001) have been implicated in the phosphorylation of 4E-BP1 under certain conditions.
Although studies have demonstrated that PTX upregulates the PI3K/Akt signaling pathway, modifications in the expression and/or phosphorylation of translation initiation proteins in response to PTX treatment have received little attention.
In this study, we examined whether PTX changes the expression and/or phosphorylation of eIF-4E and 4E-BP1. We found that PTX induced the hyperphosphorylation of 4E-BP1, which reduced its association with eIF-4E and increased the association of eIF-4E to eIF-4G, suggesting that PTX increases the functional activity of eIF-4E. In addition, cotreatment with cdk inhibitors and decreasing the expression of cyclin B using RNA interference resulted in a reduction in the hyperphosphorylated form of 4E-BP1 in PTX-treated cells, suggesting that the mechanism by which PTX alters the phosphorylation of 4E-BP1 involves cyclin B-cdk1.
Results

PTX induces the hyperphosphorylation of 4E-BP1 and reduces the association of 4E-BP1 with eIF-4E
Cancer therapeutic intervention activates signaling pathways, which enhance cell survival (Johnstone et al., 2002) , necessitating the need to delineate the signaling pathways promoted by specific therapies. PTX treatment initiates the PI3K/Akt signaling pathway, which could culminate in the activation of mTOR/ FRAP, thereby suppressing the function of 4E-BP1 and increasing the translation of survival proteins. This could reduce the cytotoxicity of PTX and possibly lead to the acquisition of chemoresistance.
To determine whether PTX alters the expression and/or phosphorylation of proteins involved in capdependent translation initiation, the breast cancer cell line, MDA MB 231, was treated with increasing concentrations of PTX for 24 h. As shown in Figure 1 , PTX treatment results in the hyperphosphorylation of 4E-BP1 as assessed by differences in gel mobility (a), which directly correlated with G2/M accumulation (b). In contrast, the expression (a) and phosphorylation (c) of eIF-4E were not altered by treatment. However, the hyperphosphorylation of 4E-BP1 on multiple residues is required to disrupt the binding of 4E-BP1 to eIF-4E. Therefore, in order to determine whether PTX-induced hyperphosphorylation of 4E-BP1 results in the release of eIF-4E, cells were treated with PTX or vehicle for 24 h and eIF-4E was precipitated by binding affinity using m 7 GTP-sepharose. The amount of 4E-BP1 and eIF-4G bound to eIF-4E was determined by immunoblot. As shown in Figure 1d , the amount of 4E-BP1 bound to eIF-4E was dramatically reduced, while the amount of eIF-4G bound to eIF-4E increased in PTX-treated cells as compared to the control. These results demonstrate that PTX does change the phosphorylation status of the translation initiation suppressor protein, 4E-BP1, in breast cancer cells. This, in turn, results in the disassociation of 4E-BP1 from eIF-4E, thereby increasing the functional activity of eIF-4E, as suggested by the increased binding of eIF-4E to eIF-4G.
PTX treatment blocks cells in M phase
PTX has been reported to block cells in G2/M phase (Mollinedo and Gajate, 2003) . In order to narrow down the number of kinase moieties that could be responsible for the hyperphosphorylation of 4E-BP1 in response to PTX, it was necessary to determine whether PTX induces M-phase accumulation in our model system.
In concert with the hyperphosphorylation of 4E-BP1 and G2/M accumulation, the putative active form (upper protein band) of the G2/M phosphatase, Cdc25C, appeared in PTX-treated cells (Figure 1a) . The dephosphorylation of Cdc25C on serine 216 promotes its nuclear translocation during M-phase transition (Bulavin et al., 2003) , resulting in its phosphorylation and increased activity (Takizawa and Morgan, 2000) . As shown in Figure 2 , the upper Cdc25C protein band is not phosphorylated on serine 216 (Figure 2a) , suggesting that the upper band is the active form of Cdc25C. PTX also increased the expression of phosphorylated histone H3 (a mitotic marker) (Figure 2b ), upregulated putative cyclin B-cdk1 activity as implied by an increase in cdk1-substrate phosphorylation ( Figure 2c ) and increased the expression of the cyclin B-cdk1 substrate, survivin (Figure 2d ). In addition, treatment with the microtubule poison, nocodazole, which arrests cells in M phase (Mollinedo and Gajate, 2003) , replicated the changes induced by PTX (Figure 2e ). Taken together, our data suggest that PTX induces mitotic arrest under these conditions in our model system.
PTX induces the hyperphosphorylation of 4E-BP1 via a cdk1-dependent mechanism
Due to the fact that PTX treatment resulted in an increase in the phosphorylation and expression of cyclin B-cdk1 substrates, cyclin B-cdk1 presented as a viable candidate, which phosphorylates 4E-BP1 in response to PTX treatment. In order to assess this possibility, MDA MB 231 cells were treated with the histone deacetylase (HDAC) inhibitor, sodium butyrate (NaB), alone or in combination with PTX. HDAC inhibitors decrease cdk1 activity indirectly by decreasing the expression of cyclins A and B and by increasing the expression of p21 (Greenberg et al., 2001) . As expected, treatment with NaB downregulated the expression of cyclin B and did not alter the phosphorylation pattern of 4E-BP1 or Cdc25C, whereas cells treated with PTX expressed high levels of cyclin B and increased the phosphorylation of 4E-BP1 and Cdc25C. In comparison, the NaB : PTX combination resulted in a reduction in the expression of the hyperphosphorylated form of 4E-BP1, the active form of Cdc25C, and cyclin B in PTX-treated cells ( Figure 3 ).
To examine more directly whether cyclin B-cdk1 was responsible for the hyperphosphorylation of 4E-BP1, cells were treated with PTX or vehicle for 24 h, then treated for an additional 6 h with the cdk inhibitors, purvalanol A and roscovitine. Purvalanol A and roscovitine competitively bind to the ATP pocket of cdk1, cdk2, cdk5 and cdk7, preventing their activation (Bain et al., 2003; Meijer and Raymond, 2003) . As shown in Figure 4 , purvalanol A and roscovitine treatment downregulated the hyperphosphorylation of 4E-BP1 and Cdc25C (a) in PTX-treated cells even though the majority of cells remained in M phase (b). Therefore, the inhibition of 4E-BP1 and Cdc25C phosphorylation in PTX-treated cells by these reagents is consistent with the inhibition of cdk1, but not conclusive. Owing to the fact that NaB downregulates the expression of cyclin B and cyclin A (Greenberg et al., 2001) , and purvalanol A and roscovitine inhibit the GTP-sepharose 24 h after treatment as described in Materials and methods. Affinity-precipitated proteins were resolved by SDS-electrophoresis and analysed by immunoblotting with antibodies specific for eIF-4G, eIF-4E, and 4E-BP1. Results are representative of three experiments Cdk1-mediated phosphorylation of 4E-BP1 VL Greenberg and SG Zimmer activity of cdk1, cdk2, cdk5 and cdk7, and non-cdkrelated kinase moieties (Bain et al., 2003) , a kinase other than cyclin B-cdk1 could be responsible for the hyperphosphorylation of 4E-BP1 by PTX.
In order to address this possibility, cyclin B expression was attenuated using small interfering RNA (siRNA) technology. Cells were transfected with siRNA specific for cyclin B or with a control nontargeting siRNA. The cells were treated 24 h post-transfection with 25 nM PTX or vehicle and harvested 24 h later. Immunoblot analysis ( Figure 5 ) showed that 100 nM of cyclin B siRNA was sufficient to dramatically reduce the expression of cyclin B, which in turn reduced cyclin B-cdk1 activity as assessed by the reduction in the amount of cdk1 substrate phosphorylation. Inhibiting the expression of cyclin B blocked the hyperphosphorylation of 4E-BP1 and Cdc25C in response to PTX, providing further evidence that cyclin B-cdk1 is involved in the hyperphosphorylation of 4E-BP1 by PTX.
The relevance of PTX-induced hyperphosphorylation of 4E-BP1 depends on whether the release of eIF-4E promotes the assembly of the eIF-4F translation initiation complex via the increased binding of eIF-4E to eIF-4G. As shown previously (Figure 1d ), the hyperphosphorylation of 4E-BP1 by PTX results in an increase in the amount of eIF-4G bound to eIF-4E. Of equal importance is whether interfering with PTXinduced hyperphosphorylation of 4E-BP1 blocks the release of eIF-4E and its subsequent binding to eIF-4G. To address this issue, cells were treated with PTX or vehicle (dimethyl sulfoxide (DMSO)) for 24 h then treated with purvalanol A or vehicle (DMSO) for an additional 6 h. eIF-4E was precipitated by binding affinity using m 7 GTP-sepharose and the amount of eIF-4G and 4E-BP1 bound to eIF-4E was analysed by immunoblotting. As shown in Figure 6a , the amount of eIF-4G which co-precipitated with eIF-4E increased in cells treated with PTX, while the amount of 4E-BP1 Cdk1-mediated phosphorylation of 4E-BP1 VL Greenberg and SG Zimmer decreased relative to the controls. In comparison, cotreatment with the cdk inhibitor, purvalanol A, prohibited the increase in eIF-4G and the reduction in 4E-BP1 levels co-precipitating with an equivalent amount of eIF-4E. These data indicate that treatment with PTX increases the binding of eIF-4E to eIF-4G by promoting the phosphorylation and release of 4E-BP1 from eIF-4E, whereas cotreatment with a purvalanol A blocked the binding of eIF-4E to eIF-4G due to the inhibition of the hyperphosphorylation of 4E-BP1 in PTX-treated cells. The serine-threonine kinase mTOR/FRAP, the downstream effector of the PI3K/Akt pathway, is responsible for the phosphorylation of 4E-BP1 on Thr-37/46. The phosphorylation of 4E-BP1 on Thr-37/ 46 is reportedly required for the phosphorylation of 4E-BP1 at other sites, which are necessary to disrupt the binding of 4E-BP1 to eIF-4E Mothe-Satney et al., 2000a, b) . In addition, treatment with PTX has been associated with the activation of mTOR in the mitotic phase of the cell cycle (Asnaghi et al., 2004) . Therefore, inhibiting mTOR or PI3K activity should inhibit the hyperphosphorylation of 4E-BP1 in response to PTX.
In order to test whether mTOR is involved in the PTX-induced hyperphosphorylation of 4E-BP1, cells were treated with PTX for 24 h, followed by cotreatment with the mTOR inhibitor, rapamycin (50 nM) or the PI3K inhibitor, wortmanin (2 mM) for an additional 6 h. Surprisingly, cotreatment with rapamycin or wortmanin failed to prevent the hyperphosphorylation of 4E-BP1 by PTX (Figure 6b) . Interestingly, we found that PTX increased the phosphorylation of the mTOR target, p70S6K Thr-389. The p70S6 kinase directly phosphorylates the 40S ribosomal protein S6, which is thought to positively impact cap-dependent translation (Fingar and Blenis, 2004) . However, cotreatment with rapamycin or wortmanin did not downregulate the phosphorylation of p70S6K Thr-389, whereas cotreatment with purvalanol A and roscovitine did decrease the phosphorylation level of p70S6 K Thr-389.
Overall, our data strongly suggest that cyclin B-cdk1 is involved in the phosphorylation of 4E-BP1 in response to PTX treatment. Whether this involvement is direct or indirect is not known.
PTX-induced phosphorylation of 4E-BP1 is not tissue specific
The etiology of cancerous lesions is in part tissue specific (Minamoto and Ronai, 2001) . To determine whether the hyperphosphorylation of 4E-BP1 in response to PTX is restricted to breast cancer, the advent of 4E-BP1 phosphorylation by PTX was examined in a panel of cell lines derived from ovarian, thyroid, colon and cervical tumors. The cell lines were treated with a concentration of PTX sufficient to induce a significant (>50%) G2/M accumulation (data not shown). We found that PTX induced the hyperphosphorylation 4E-BP1 in the entire set of cell lines tested (Figure 7) . Although the extent of the hyperphosphorylation of 4E-BP1 varies within the cell lines tested, this most likely reflects the percentage of cells in G2/M induced by 25 nM PTX in 24 h. For example, 4E-BP1 is hyperphosphorylated to a lesser extent in the HeLa cell line (G2/ M ¼ 65.5%) as compared to the HCT116 cell line (G2/ M ¼ 91.5%). These results indicate that the hyperphosphorylation of 4E-BP1 in response to PTX is a general phenomenon and not limited to the MDA MB 231 breast cancer cell line.
Discussion
PTX is a microtubule poison and a widely used chemotherapeutic agent. Even though PTX prevents cell division by stabilizing microtubules, alterations in protein expression and activity, which positively and negatively impact cell survival, have been reported (Mollinedo and Gajate, 2003) . Thus, the induction of conflicting signals could reduce the cytotoxic efficacy of this drug.
PTX treatment reportedly induces persistent activation of cyclin B-cdk1 (O'Connor et al., 2002; Mollinedo and Gajate, 2003) which, in turn, can lead to the upregulation of the IAP, survivin. Cyclin B-cdk1-dependent phosphorylation of survivin increases its stability, which in turn increases the level of survivin protein (Altieri, 2003) . In agreement with this study, we found that PTX treatment of breast cancer cells increased cyclin B-cdk1 activity, as implied by the increase in overall cdk1-substrate phosphorylation and the increase in survivin protein levels. Figure 3 The HDAC inhibitor, NaB, decreases PTX-induced hyperphosphorylation of 4E-BP1. MDA MB 231 cells were treated with vehicle (DMSO), 5 mM NaB, 25 nM PTX or with a combination of 5 mM NaB and 25 nM PTX and harvested after 24 h. Protein extracts were prepared, resolved by SDS electrophoresis and expression was examined by immunoblotting with antibodies specific for Cdc25C, cyclin B, eIF-4E, and 4E-BP1 as described in Materials and methods. Results are representative of three experiments Cdk1-mediated phosphorylation of 4E-BP1 VL Greenberg and SG Zimmer PTX also activates the PI3K/Akt signaling pathway, which is an important regulator of cap-dependent translation (Vivanco and Sawyers, 2002) . Formation of the eIF-4F initiation complex is promoted by the concentration of the rate-limiting factor in protein translation, eIF-4E (Zimmer et al., 2000; Meric and Hunt, 2002; Mamane et al., 2004) . The activity of eIF-4E is regulated by protein levels and by its association with small inhibitory 4E-BPs. The phosphorylation of 4E-BP1 reduces its binding affinity for eIF-4E and promotes its release from eIF-4E, thereby increasing eIF-4E functional activity Pause et al., 1994; Raught and Gingras, 1999) .
The serine-threonine kinase mTOR/FRAP, the downstream effector of the PI3K/Akt pathway, is responsible for the priming phosphorylations of 4E-BP1. The phosphorylation of these residues (Thr 37/46) is thought to be necessary to secure the release of 4E-BP1 from eIF-4E through additional phosphorylation (Ser-65, Thr-70) events MotheSatney et al., 2000a, b) . Although the kinase responsible for these phosphorylations have not been clearly defined, cyclin B-cdk1 has been implicated in the phosphorylation of 4E-BP1 (Thr-70) during the mitotic phase of the cell cycle (Heesom et al., 2001 ). With this in mind, we sought to determine whether PTX treatment changes the functional activity of eIF-4E by altering the expression and/or phosphorylation of eIF-4E or 4E-BP1 and to determine its molecular basis.
We found that PTX induced the hyperphosphorylation of 4E-BP1, which reduced its association with eIF-4E and increased the association of eIF-4E with eIF-4G. These data suggest that treatment with PTX could decrease the suppressor function of 4E-BP1 by increasing its phosphorylation, possibly enhancing cell survival. Wendel et al. (2004) found that the overexpression of Akt or eIF-4E enhanced chemoresistance and promoted tumorigenesis by increasing cell survival. Alternatively, reducing the functional level of eIF-4E through the overexpression of wild-type 4E-BP1 and phosporylation site mutants (Avdulov et al., 2004) or by overexpressing specific eIF-4E-binding peptides (Herbert et al., 2000) promotes cell death.
Our data suggested that a kinase, active in G2/M, such as cyclin B-cdk1, was involved in the hyperphosphorylation of 4E-BP1 in PTX-treated cells. In order to determine whether cyclin B-cdk1 was involved in the phosphorylation of 4E-BP1 in response to PTX, we cotreated cells with a number of agents which inhibit cyclin B-cdk1 kinase activity. We found that Cdk1-mediated phosphorylation of 4E-BP1 VL Greenberg and SG Zimmer cotreatment with the HDAC inhibitor, NaB, blocked the hyperphosphorylation of 4E-BP1 by PTX and reduced the expression of cyclin B protein levels. In our previous studies, treatment with NaB reduced cdk1 kinase activity which was associated with the decreased expression of cyclins A and B and the increased expression of p21 (Greenberg et al., 2001) . In conjunction with using an indirect inhibitor, we tested whether treatment with the direct cdk1 inhibitors, purvalanol A and roscovitine, could block the effect of PTX treatment with respect to 4E-BP1. We found that cotreatment with purvalanol A and roscovitine downregulated the hyperphosphorylation of 4E-BP1. Although the position in the cell cycle and the effect on known cyclin B-cdk1 target proteins is consistent with cyclin B-cdk1 function, other possibilities exist. For example, we found that treatment with the PP2A inhibitor, okadaic acid, produced results similar to those brought about by PTX, including G2/M accumulation and hyperphosphorylation of 4E-BP1 and Cdc25C (data not shown). These data suggest that PTX might act as a PP2A suppressor. PP2A is active in G2/M and dephosphorylates multiple substrates, including 4E-BP1, p70 S6 K, and Cdc25C (Janssens and Goris, 2001) . Finally, using a more direct approach to assess the involvement of cyclin B-cdk1 in the hyperphosphorylation of 4E-BP1, we selectively reduced cyclin B protein levels using siRNA technology. We found that reducing the protein expression of cyclin B with specific siRNAs blocked the hyperphosphorylation of 4E-BP1 and Cdc25C in response to PTX. These data provide further evidence that cyclin B-cdk1 is involved in the hyperphosphorylation of 4E-BP1 by PTX.
The significance of PTX-induced hyperphosphorylation of 4E-BP1 depends on whether the release of eIF-4E promotes the assembly of the eIF-4F translation initiation complex via the increased binding of eIF-4E to eIF-4G. We demonstrate that the amount of eIF-4E bound to eIF-4G increased in cells treated with PTX. In comparison, the amount of 4E-BP1 bound to eIF-4E GTPsepharose as described in Materials and methods. eIF-4E and its associated proteins were resolved by SDS electrophoresis and analysed by immunoblotting with antibodies specific for eIF-4G, eIF-4E, and 4E-BP1. Results are representative of three experiments. (b) MDA MB 231 cells were treated with vehicle (DMSO) or with 25 nM PTX. The inhibitors, purvalanol A (10 mM), roscovitine (50 mM), rapamycin (50 nM), or wortmanin (2 mM), were added 24 h later. The cells were incubated for an additional 6 h and harvested 30 h after initial treatment. Protein extracts were prepared, resolved by SDS electrophoresis and expression was examined by immunoblotting with antibodies specific for phospho-p70S6K (Thr389), Cdc25C, b-actin, and 4E-BP1. Results using wortmanin alone were identical to PTX/wortmannin (data not shown). Results are representative of three experiments Cdk1-mediated phosphorylation of 4E-BP1 VL Greenberg and SG Zimmer decreased in cells treated with PTX. In contrast, cotreatment with the cdk inhibitor, purvalanol A, blocked the increase in eIF-4E bound to eIF-4G due to the inhibition of the hyperphosphorylation of 4E-BP1 and release in PTX-treated cells. These data indicate that treatment with PTX increases the binding of eIF-4E to eIF-4G by promoting the phosphorylation and release of 4E-BP1 from eIF-4E.
Next, we sought to determine whether mTOR/FRAP, the downstream effector of the PI3K/AKT pathway, is involved in the phosphorylation of 4E-BP1. mTOR/ FRAP is reported to be responsible for the priming phosphorylation of 4E-BP1 in response to growth factors, insulin, and cell stress Mothe-Satney et al., 2000a, b) . Therefore, inhibiting mTOR or PI3 K activity should inhibit the hyperphosphorylation of 4E-BP1 in response to PTX.
We were surprised that cotreated with rapamycin or wortmanin did not block the hyperphosphorylation of 4E-BP1 by PTX or decrease the phosphorylation of p70S6 K on Thr-389, the amino-acid residue phosphorylated by mTOR in vitro (Fingar and Blenis, 2004) . A plausible explanation for these results is that the inactivation of mTOR by rapamycin, which reportedly increases PP2A activity (Peterson et al., 1999) , is unable to overcome the suppression of PP2A by PTX. This prevents the PP2A-mediated dephosphorylation of 4E-BP1 and p70S6K. As noted previously, we found that treatment with the PP2A inhibitor, okadaic acid, results in the hyperphosphorylation of 4E-BP1 and Cdc25C in a manner similar to PTX (data not shown). However, this hypothesis has yet to be tested. Interestingly, PTX upregulated the phosphorylation of p70S6K (Thr-389) and cotreatment with purvalanol A and roscovitine inhibited this increase, suggesting that cyclin B-cdk1 is involved in the phosphorylation of p70S6K (Thr-389). Cyclin B-cdk1 has been shown to phosphorylate p70S6K on Ser-411 and Thr-421/424 (Papst et al., 1998; Shah et al., 2003) . However, cyclin B-cdk1 has not been directly linked to the phosphorylation of p70S6K (Thr-389). Conversely, cyclin B-cdk1 activity might be required for mTOR-dependent phosphorylation of Thr-389 or mTOR is not responsible for the phosphorylation of p70S6 K (Thr-389) under these stress conditions.
The implication that cyclin B-cdk1 phosphorylates 4E-BP1 in response to PTX is that treatment with this drug could produce counteractive signals, which both promote and inhibit cell survival. This, in theory, could lead to the acquisition of chemoresistence. Therefore, treatment with drugs, such as taxanes, that arrest cells in M phase and cause a persistent activation of M-phase kinases, should be combined with drugs that reduce cdk1 activity such as flavopiridol and the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA). Both flavopiridol and SAHA are currently in clinical trials (Kelly et al., 2003; Shapiro, 2004) .
A recent study in our laboratory demonstrated that treatment with HDAC inhibitors increased the cytotoxic efficacy of PTX in ovarian cancer cell lines (Chobanian et al., 2004) . Whether this increase in cell death is related to changes in the phosphorylation of 4E-BP1 is not known. We are currently testing whether blocking 4E-BP1 hyperphosphorylation accelerates or augments PTX-induced cell death. Overall, our data strongly suggest that cyclin B-cdk1 is involved in the hyperphosphorylation of 4E-BP1 in response to PTX treatment. Whether this involvement is direct or indirect is not known.
Materials and methods
Reagents
PTX, nocodazole (Sigma-Aldrich, St Louis, MO, USA), rapamycin, wortmannin, purvalanol A and roscovitine (Calbiochem, La Jolla, CA, USA) were dissolved in DMSO (Sigma) and NaB (Sigma) was dissolved in culture medium. Sheep anti-mouse and goat anti-rabbit horseradish peroxidaselinked antibodies and 7-methyl GTP-sepharose were purchased from Amersham Biosciences, Arlington Heights, IL, USA. Antibodies specific for eIF-4E and cyclin B were purchased from BD Biosciences, San Diego, CA, USA; b-actin antibody was purchased from Sigma; Cdc25C, survivin, eIF-4G, and p-eIF-4E (Ser-209) antibodies were purchased from Santa Cruz, Santa Cruz, CA, USA; 4E-BP1/PHAS I antibody was purchased from Zymed, San Francisco, CA, USA; phospho-histone H3 was purchased from Upstate, Lake Placid, NY, USA; and phospho-p70 S6 Kinase (Thr389) and phospho-Cdc25C (Ser216) were purchased from Cell Signaling, Beverly, MA, USA. The phospho-cdk1 substrate antibody, which was generated using a phosphopeptide analogous to a consensus recognition sequence for cdk1, was purchased from Oncogene Research Products, San Diego, CA, USA.
Cell culture
The human breast cancer cell line, MDA MB 231, and cervical carcinoma cell line, HeLa, were purchased from the American Type Culture Collection, Manassas, VA, USA. The human epithelial ovarian cancer cell lines, A2780 and SKOV3, were kindly provided by Dr Michael Birrer, NCI, Bethesda, MD, USA; the human anaplastic thyroid cancer cell lines, DRO90-1 Figure 7 The hyperphosphorylation of 4E-BP1 in response to PTX is not tissue specific. Cell lines derived from breast (MDA MB 231), colon (HCT116 and HCT116 p21À/À), cervical (HeLa), ovarian (A2780 and SKOV3), and thyroid (ARO81-1 and DRO90-1) tumors were treated with vehicle (DMSO) or 25 nM PTX and the cells were harvested after 24 h. Protein extracts were prepared, resolved by SDS electrophoresis and expression was examined by immunoblotting with an antibody specific for 4E-BP1 as described in Materials and methods. Results are representative of three experiments À/À cell lines were cultured in minimum essential medium Eagle (MEM) (Gibco/BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Sigma), 1% MEM non-essential amino acids solution (Gibco/BRL) and 50 U/ml of penicillin G, and 50 mg/l of streptomycin sulfate (Gibco/BRL). The A2780, SKOV3, DRO90-1, and ARO81-1 cell lines were cultured in RPMI 1640 (Gibco/BRL) supplemented with 10% fetal bovine serum and 100 U/ml of penicillin G and 100 mg/l of streptomycin sulfate. The cells were grown at 371C/5% CO 2 /100% humidity.
Cell cycle analysis
Cells were plated at a density of 5 Â 10 5 per 12 ml in complete media and were treated with drug at the concentrations indicated in the figure legends. Cells were harvested by combining the culture medium and trypsinized monolayer at the time indicated in the figure legends. The cell pellet was washed 1 Â in PBS, fixed in a 70% solution of ethanol and DNA content was analysed as described previously (Greenberg et al., 2001) .
Western blot analysis
Cells were collected as described above, washed 1 Â with PBS, counted and pelleted by centrifugation. Protein extracts were prepared and separated by electrophoresis through 4-20% Tris glycine or 3-8% Tris acetate gels (Invitrogen, Carlsbad, CA, USA) as described previously (Greenberg et al., 2001) . Membranes were incubated with primary antibodies overnight at 41C, washed and incubated with the appropriate HRPlinked secondary antibody at room temperature for 1 h. Protein bands were visualized using a chemiluminescent ECL kit (Amersham) as instructed by the manufacturer.
SiRNA transfection
Control nontargeting siRNA and cyclin B siRNA (Dharmacon, Lafayette, CO, USA) were transfected into MDA MB 231 cells using oligofectamine reagent according to the manufacturer's recommendations (Invitrogen). Briefly, cells were plated in six-well tissue culture plates at a density of 2 Â 10 5 per well in complete medium, without antibiotics. The following day, the growth medium was removed and each well was washed once with serum-free medium. Complex formation between the siRNA and oligofectamine reagent was accomplished as stated in the protocol. Serum-free medium (800 ml) and the appropriate siRNA/oligofectamine combination were added to each well at the concentration as stated in the figure legend. The culture dishes were incubated at 371C/5% CO 2 /100% humidity for 4 h and 500 ml of 30% MEM (without antibiotics) was added to each well. Cells were treated with vehicle (DMSO) or 25 nM PTX, 24 h after transfection. Cells were harvested 24 h later by combining the monolayer and supernatant, washing once in warm PBS, and resuspending the cell pellet in 80 ml of boiling 2 Â lysis buffer. Protein extracts were stored at À201C.
7-Methyl GTP-sepharose affinity precipitation
MDA MB 231 cells were treated as indicated in the figure legend and harvested 24 h later. Affinity precipitation of eIF-4E was conducted at 41C unless otherwise noted. Cells were washed 1 Â with PBS, then resuspended in RIPA lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% deoxycholic acid) at a concentration of 10 6 cells per 100 ml. Cell extracts were placed on ice for 5 min, then centrifuged at 16 000 g for 10 min. The supernatants were collected and 50 ml of m 7 GTP-sepharose was added to each sample. The extracts were set on ice for 60 min with intermittent mixing. The extracts were centrifuged for 10 min at 1800 r.p.m. and the sepharose pellet was washed 3 Â with RIPA lysis buffer. In all, 50 ml of boiling 2 Â Western lysis solution (125 mM Tris-HCl pH 6.8, 4% SDS, 10% glycerol, 2% b-mercaptoethanol, 0.006% bromophenol blue) was added to the sepharose pellet and the precipitated proteins were analysed by immunoblotting as described.
